title: Aerosol performance and long-term stability of surfactant-associated liposomal ciprofloxacin formulations with modified encapsulation and release properties.
abstract: Previously, we showed that the encapsulation and release properties of a liposomal ciprofloxacin formulation could be modified post manufacture, by addition of surfactant in concert with osmotic swelling of the liposomes. This strategy may provide more flexibility and convenience than the alternative of manufacturing multiple batches of liposomes differing in composition to cover a wide range of release profiles. The goal of this study was to develop a surfactant-associated liposomal ciprofloxacin (CFI) formulation possessing good long-term stability which could be delivered as an inhaled aerosol. Preparations of 12.5 mg/ml CFI containing 0.4% polysorbate 20 were formulated between pH 4.7 and 5.5. These formulations, before and after mesh nebulization, and after refrigerated storage for up to 2 years, were characterized in terms of liposome structure by cryogenic transmission electron microscopy (cryo-TEM) imaging, vesicle size by dynamic light scattering, pH, drug encapsulation by centrifugation-filtration, and in vitro release (IVR) performance. Within the narrower pH range of 4.9 to 5.2, these formulations retained their physicochemical stability after 2-year refrigerated storage, were robust to mesh nebulization, and formed respirable aerosols with a volume mean diameter (VMD) of 3.7 μm and a geometric standard deviation (GSD) of 1.7. This study demonstrates that it may be possible to provide a range of release profiles by simple addition of surfactant to a liposomal formulation post manufacture, and that these formulations may retain their physicochemical properties after long-term refrigerated storage and following aerosolization by mesh nebulizer.
authors.affiliation: Advanced Drug Delivery Group, Faculty of Pharmacy, The University of Sydney, Pharmacy Building A15, Sydney, NSW, 2006, Australia, cipollad@aradigm.com.
authors.forename: David
authors.initials: D
authors.lastname: Cipolla
authors.forename: Huiying
authors.initials: H
authors.lastname: Wu
authors.forename: Igor
authors.initials: I
authors.lastname: Gonda
authors.forename: Hak-Kim
authors.initials: HK
authors.lastname: Chan
mesh_terms: D000336:Aerosols; D000900:Anti-Bacterial Agents / Q000008:administration & dosage*; D002626:Chemistry, Pharmaceutical; D002939:Ciprofloxacin / Q000008:administration & dosage*; D003692:Delayed-Action Preparations; D004339:Drug Compounding; D004355:Drug Stability; D006863:Hydrogen-Ion Concentration; D008081:Liposomes; D010316:Particle Size; D057285:Precision Medicine; D013501:Surface-Active Agents / Q000737:chemistry*
chemical_list: D000336:Aerosols; D000900:Anti-Bacterial Agents; D003692:Delayed-Action Preparations; D008081:Liposomes; D013501:Surface-Active Agents; D002939:Ciprofloxacin